IGIan S. Grimm

Ian S. Grimm

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ian S. Grimm has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 120 DIAGNOSTIC ACCURACY OF HIGH DEFINITION WHITE LIGHT, NARROW BAND IMAGING WITH OR WITHOUT NEAR FOCUS FOR ASSESSMENT OF COLORECTAL ENDOSCOPIC MUCOSAL RESECTION SCARS: ESCART TRIAL (EMR SCAR ASSESSMENT TRIAL), MULTICENTER IMAGE EVALUATION STUDY

    by Pujan Kandel, Eelco C. Brand, Joe Pelt, Gottumukkala S. Raju, Douglas K. Rex, Dennis Yang, Mohammad A. Al-Haddad, Peter Draganov, Jeffrey Gill, Cesare Hassan, et al.


  • Hilar cholangiocarcinoma diagnosed by endoscopic ultrasound-guided hepaticogastrostomy and cholangioscopy

    by Theodore W. James, Ian S. Grimm, Todd H. Baron

    A 77-year-old woman, with a history of Whipple resection 20 years previously for a lesion in the porta hepatis that was later determined to be benign, was found to have elevated bilirubin and alkaline phosphatase on routine laboratory testing, prompting a computed tomography (CT) scan of the abdomen ([Fig. 1]). This showed intrahepatic ductal dilatation and pancreatic duct prominence. The patient was referred for gastroenterological investigation with concern for malignancy versus autoimmune cholangiopathy. Single-balloon endoscopic retrograde cholangiopancreatography (ERCP) was attempted but was unable to reach the hepaticojejunostomy. Endoscopic ultrasonography (EUS) was employed to visualize the biliary tree, and demonstrated dilatation of the left intrahepatic bile duct. The duct was punctured under EUS guidance, and a fully covered metal stent was placed from the left hepatic duct into the stomach. A cholangiogram was obtained through the hepaticogastrostomy, and demonstrated hilar stricturing with a patent hepaticojejunostomy ([Fig. 2]). Both the left and right hepatic ducts were decompressed through the hepaticogastrostomy ([Fig. 3]). A second examination was performed with single-operator cholangioscopy through the hepaticogastrostomy ([Fig. 4]). This demonstrated ulcerated biliary mucosa; brushings were obtained for cytology and biopsies were taken. A plastic biliary stent was placed within the metal stent to allow continued drainage. Brush cytology was nondiagnostic; however biopsy tissue from the stricture demonstrated invasive adenocarcinoma. The CA19-9 level at the time of diagnosis was 563 U/mL. The patient was not a candidate for surgical resection, but chemotherapy was initiated. At 4 months after diagnosis, her biliary tree remained adequately decompressed as evidenced by near-normal liver enzyme levels. A tissue diagnosis is necessary to differentiate hilar cholangiocarcinoma from IgG4 cholangiopathy [1]. This is the first description of hilar cholangiocarcinoma diagnosed via cholangioscopy through an EUS-guided hepaticogastrostomy [2]. The case also serves to demonstrate that both hepatic ducts can be drained through a hepaticogastrostomy into the left duct, which is particularly useful in post-surgical anatomy that limits standard ERCP ([Video 1]). Video 1 Hilar cholangiocarcinoma diagnosed by endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) and cholangioscopy through the hepaticogastrostomy. Endoscopy_UCTN_Code_TTT_1AS_2AD


  • Use of a lumen-apposing metal stent to treat GI strictures (with videos)

    by Shayan Irani, Sujai Jalaj, Andrew Ross, Michael Larsen, Ian S. Grimm, Todd H. Baron


  • Lumen-apposing covered self-expandable metal stents for short-length gastrointestinal strictures: Will they take hold?

    by Todd H. Baron, Ian S. Grimm, Shayan Irani

    Benign strictures can occur throughout the gastrointestinal (GI) tract. Endoscopic therapy consists primarily of dilation with or without fluoroscopy. For esophageal and rectal strictures, this consists of balloon dilation and over-the-wire rigid (bougie) dilation. At other locations within the GI tract, through-the-scope balloon dilation is used. Endoscopic dilation is usually effective, though some patients may require one or more sessions to achieve an adequate response. Unfortunately, in a subset of patients, repeated dilation sessions are ineffective in maintaining an adequate lumen. Such refractory strictures are problematic, as there are few remaining options, and surgery is not often a simple matter in these patients. Electroincision is effective for short anastomotic and nonanastomotic strictures. Intralesional corticosteroid injection may have some efficacy in peptic esophageal strictures and inflammatory bowel disease-related strictures, but the outcome in short, anastomotic strictures often seems to benefit the endoscopist more than the patient, though it is often used as adjuvant therapy owing to its low risk and relatively low cost. “It is reasonable to consider the use of LAMS for patients in whom all other endoscopic interventions have failed.” The use of covered self-expandable stents (SEMS) for management of benign GI strictures emerged about 15 years ago, though their use remains off-label in most countries, including the United States. The initial enthusiasm for fully covered SEMS in the management of refractory strictures has dampened over the years, primarily because of high migration rates, but also because of poor efficacy in many trials. Although migration can be reduced (but not eliminated) by anchoring using endoluminal sutures [1] [2] or over-the-scope clip placement [3] [4] [5], these adjuvant therapies add additional, often nonreimbursable and substantial cost, and also prolong the procedure time. For rectal locations, anchoring at the distal side may not be effective, as the stents need to be anchored on the proximal side, which is technically more difficult because the devices need to be passed through the stent lumen, potentially causing stent dislodgment. Additional problems include stent placement for strictures located at anastomotic sites not situated proximally to an intact pylorus, such as Roux-en-Y gastrojejunostomies – situations in which distal migration into the small bowel could cause downstream bowel obstruction requiring surgical intervention. Lumen-apposing metal stents (LAMS) are of short length (1 cm) with large flanges. Currently, the largest mid-body diameter of the most commonly used stent (Axios; Boston Scientific, Marlborough, Massachusetts, USA) is 15 mm, though it is anticipated that a 20 mm stent will soon become available. LAMS were designed to anchor together two lumens not normally apposed. However, preliminary series have shown that these stents are useful for short benign strictures (< 1 cm). Advantages of LAMS are the short distance between the flanges (1 cm) and the large diameter of the flanges, which essentially “sandwich” the stricture and probably account for the low rate of migration. The Axios stent is designed specifically for passage through an echoendoscope; the delivery system attaches directly into the Luer-Lok fitting of the proximal working channel, allowing the endoscopist to deploy the stent without assistance. The endoscopic view provided by an oblique echoendoscope (the ultrasound functionality of the scope is not necessary for luminal placement) can be slightly awkward; however, the stent can also be used with therapeutic channel, forward-viewing upper endoscopes (and even duodenoscopes), for which the delivery system is excessively long and requires support. Thus, the deployment in these cases is similar to other stents, where an assistant is vital in device deployment. Notably, one endoscope manufacturer produces a forward-viewing linear echoendoscope with which Axios stent placement for strictures can easily be performed by the endoscopist without assistance (also without the use of the echo portion of the endoscope). Placement of these stents is not fluoroscopy dependent (other than ensuring proper wire passage in difficult cases) owing to the short stent length and ease of precise endoscopic visual placement (especially when forward-viewing scopes are used). Stent removal is relatively easy using grasping forceps. In this issue of Endoscopy, Yang et al. [6] provide results of a retrospective multicenter study of 30 patients who underwent successful LAMS placement for short-length (4 – 5 mm) strictures, of which nearly 90 % were (not unexpectedly) anastomotic, and most were gastrojejunal. Of the 30 patients, 27 had undergone previous multiple endoscopic therapies, including traditional SEMS placement prior to undergoing LAMS placement. LAMS migration occurred in 8 % of patients. Approximately 83 % of patients were symptom free at 100 days following stent removal. These results are substantially better than previous reports using fully covered SEMS for benign GI strictures, including a large series using LAMS from our centers, which showed a clinical success at 6 months of 61 % [7]. This may be due to a shorter median follow-up in the Yang paper. Additionally, and somewhat surprisingly, two severe early adverse events occurred – one patient with bleeding that required embolization and one patient experienced perforation that required surgical repair. It was unclear whether pre- or postdeployment dilation had been performed during placement in either of these two patients, as dilation was performed in some patients in the series even though the delivery system (10.8 Fr in diameter) should easily pass through a small (~4 mm) stenosis. Other series, one describing 5 patients [8], and another with 25 patients (including patients from our own centers) [7],...


  • EUS-guided gastroenterostomy is comparable to enteral stenting with fewer re-interventions in malignant gastric outlet obstruction

    by Yen-I Chen, Takao Itoi, Todd H. Baron, Jose Nieto, Yamile Haito-Chavez, Ian S. Grimm, Amr Ismail, Saowanee Ngamruenphong, Majidah Bukhari, Gulara Hajiyeva, et al.

    Endoscopic enteral stenting (ES) in malignant gastric outlet obstruction (GOO) is limited by high rates of stent obstruction. EUS-guided gastroenterostomy (EUS-GE) is a novel procedure that potentially offers sustained patency without tumor ingrowth/overgrowth. The aim of this study is to compare EUS-GE with ES in terms of (1) symptom recurrence and need for re-intervention, (2) technical success (proper stent positioning as determined via endoscopy and fluoroscopy), (3) clinical success (ability to tolerate oral intake without vomiting), and (4) procedure-related adverse events (AEs).


  • Open Access

    Endoscopic ultrasound fine-needle aspiration vs. fine-needle biopsy: tissue is always the issue

    by Eduardo Rodrigues-Pinto, Ian S. Grimm, Todd H. Baron

    Initially described by Vilmann et al. in 1992 [1], endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a validated diagnostic procedure in the field of gastrointestinal pathology. It is the current standard of care for sampling pancreatic mass lesions, with reported sensitivities ranging from 64 % to 95 %, specificities from 75 % to 100 %, and diagnostic accuracies from 78 % to 95 % [2]. However, the actual efficacy of EUS-FNA in practice depends on the site, size, and characteristics of the target tissue [3], as well as the availability of a cytopathologist to render an on-site diagnosis [4]. In order to overcome some of the limitations of FNA, needles designed to obtain biopsy specimens (fine-needle biopsy [FNB] needles) have been developed that allow core samples to be collected by shearing tissue from the target lesion. The expectation is that cutting needles will improve diagnostic accuracy as well as provide tissue with conserved architecture, enabling histological analysis [5]. The available literature comparing FNA and FNB needles has not provided definitive results [6] [7]. A recent meta-analysis found no significant difference between one biopsy needle (ProCore; Cook Endoscopy, Bloomington, Indiana, USA) and standard FNA needles with regard to sample adequacy, diagnostic accuracy, or acquisition of a core specimen; however, the FNB needle established a diagnosis with fewer passes [8]. In this issue of Endoscopy International Open, Aadam et al. [9] present compelling data showing significantly higher rates of diagnostic yield and specimen adequacy for solid mass lesions sampled by FNB than for those sampled by FNA for all specimens. Although the difference in diagnostic yield was not statistically significant for pancreatic lesions, one could argue that it was clinically significant, at 91.7 % compared with 78.4 %. A maximum of three passes was allowed for the first method of EUS tissue acquisition, and then patients were crossed over to the other type of needle based on on-site specimen adequacy. The differences were independent of lesion size, number of passes, use of suction or stylet, and needle gauge. The authors concluded that FNB should also be favored over FNA as a salvage technique when inadequate samples are obtained with FNA. Analysis of cost-effectiveness from the perspective of a third-party payer (not representative of the methodology used in the randomized, controlled trial with crossover design) showed that FNB was more cost-effective than FNA for both pancreatic and nonpancreatic masses. This analysis included the use of on-site pathology for all examinations. The lack of standardization of needle sizes is one weakness in the study design. Another concern is that the analysis of the crossover salvage effect may have been limited by the restricted number of passes that could be made with the initial needle. Previous experience with brush cytology for the diagnosis of biliary strictures and the potential role of dilation before or after sampling demonstrated that the increased sensitivity observed following stricture dilation was most likely a consequence of the act of obtaining additional samples [10]. As the authors recognize, there are significant cost implications associated with choice of needle and diagnostic strategy. If the routine use of FNB needles could provide diagnostic yields high enough to eliminate the need for on-site cytopathological evaluation, then there would be not only a reduction in direct costs but also a significant reduction in opportunity costs (costs associated with lost time pending cytological interpretation feedback). In fact, costs associated with downtime could ultimately prove to be the dominant driver in decision analysis. Total procedural time might be cut in half by performing FNB without on-site evaluation, potentially reducing hospital and anesthesia charges as well. The use of FNB as a salvage technique following unsuccessful FNA may not be cost-saving because this strategy requires two needles and extra time for additional passes; FNB alone may well be the dominant strategy for nonpancreatic lesions. However, if an FNB-alone strategy is used, it is imperative to determine the optimal number of passes and the needle gauge required to obtain a reliable diagnosis and exclude malignancy, and whether these variables differ by target organ. In theory, in the acquisition of a tissue core, EUS-FNB should be superior to FNA if needle design can be perfected. The day may soon come when EUS-FNB is analogous to tissue acquisition for mucosal lesions, in which samples are reliably obtained without the need for an on-site cytopathologist. Assuming that biopsy specimens are obtained from the lesion of interest and sampling is adequate, we might expect high diagnostic yields. Four strategies are now available for obtaining tissue during EUS: FNA, FNB, both, and FNA with salvage FNB if the FNA samples are nondiagnostic. Ideally, a prospective blinded study should be conducted in which FNA and FNB are performed at the same site during the same endoscopic session with needles of matching gauges, similar to the one performed by Lin et al. [11], so that the diagnostic yields of EUS-FNA with on-site cytopathology and EUS-FNB without on-site pathology can be compared. Nevertheless, the current study by Aadam et al. is a significant step in the evolution of FNB, which may ultimately become the preferred method for EUS-guided tissue acquisition.